These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 32348994)
1. Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia. Poh C; Arora M; Ghuman S; Tuscano J Acta Haematol; 2021; 144(1):95-99. PubMed ID: 32348994 [TBL] [Abstract][Full Text] [Related]
2. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. Campbell P; Thomas CM J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086 [TBL] [Abstract][Full Text] [Related]
3. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246 [TBL] [Abstract][Full Text] [Related]
4. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. Rashidi A; Cashen AF Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217 [TBL] [Abstract][Full Text] [Related]
5. Long-term successful use of belinostat in a patient with relapsed-refractory angioimmunoblastic lymphoma who has previously been heavily treated. Atalay F; Yeşilaltay A J Cancer Res Ther; 2024 Apr; 20(3):1049-1052. PubMed ID: 39023617 [TBL] [Abstract][Full Text] [Related]
6. Metronomic regimen as an effective treatment for aggressive T-LGL leukemia with central nervous system infiltration: clinical experience and review of literature. Liu Y; Fan L; Zhao H; Xu W; Li J Oncotarget; 2017 May; 8(19):32292-32297. PubMed ID: 28427176 [TBL] [Abstract][Full Text] [Related]
7. Belinostat: first global approval. Poole RM Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672 [TBL] [Abstract][Full Text] [Related]
8. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. Zhu Y; Gao Q; Hu J; Liu X; Guan D; Zhang F Leuk Res; 2020 Mar; 90():106299. PubMed ID: 32035354 [TBL] [Abstract][Full Text] [Related]
9. Choroidal Infiltration as First Clinical Manifestation of T-cell Large Granular Lymphocyte (T-LGL) Leukemia. Sarny S; Beham-Schmid C; El-Shabrawi Y Ocul Immunol Inflamm; 2020 Oct; 28(7):1133-1135. PubMed ID: 31577464 [No Abstract] [Full Text] [Related]
10. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Puvvada SD; Li H; Rimsza LM; Bernstein SH; Fisher RI; LeBlanc M; Schmelz M; Glinsmann-Gibson B; Miller TP; Maddox AM; Friedberg JW; Smith SM; Persky DO Leuk Lymphoma; 2016 Oct; 57(10):2359-69. PubMed ID: 26758422 [TBL] [Abstract][Full Text] [Related]
12. T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience. Sretenovic A; Antic D; Jankovic S; Gotic M; Perunicic-Jovanovic M; Jakovic L; Mihaljevic B Med Oncol; 2010 Jun; 27(2):286-90. PubMed ID: 19306076 [TBL] [Abstract][Full Text] [Related]
13. Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature. Alekshun TJ; Tao J; Sokol L Am J Hematol; 2007 Jun; 82(6):481-5. PubMed ID: 17205534 [TBL] [Abstract][Full Text] [Related]
14. Belinostat for the treatment of peripheral T-cell lymphomas. McDermott J; Jimeno A Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834 [TBL] [Abstract][Full Text] [Related]
15. Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate. Munir T; Bishton MJ; Carter I; McMillan A; O'Connor S; Sovani V; Haynes AP; Fox CP Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):705-712. PubMed ID: 27640075 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. Giaccone G; Rajan A; Berman A; Kelly RJ; Szabo E; Lopez-Chavez A; Trepel J; Lee MJ; Cao L; Espinoza-Delgado I; Spittler J; Loehrer PJ J Clin Oncol; 2011 May; 29(15):2052-9. PubMed ID: 21502553 [TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Kirschbaum MH; Foon KA; Frankel P; Ruel C; Pulone B; Tuscano JM; Newman EM Leuk Lymphoma; 2014 Oct; 55(10):2301-4. PubMed ID: 24369094 [TBL] [Abstract][Full Text] [Related]
19. [Hepatocellular failure revealing T-cell large granular lymphocyte leukemia: Morocco case study and literature review]. Benmoussa A; Oussaih L; Tazi I Pan Afr Med J; 2019; 34():119. PubMed ID: 31934260 [TBL] [Abstract][Full Text] [Related]
20. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. Lee HZ; Kwitkowski VE; Del Valle PL; Ricci MS; Saber H; Habtemariam BA; Bullock J; Bloomquist E; Li Shen Y; Chen XH; Brown J; Mehrotra N; Dorff S; Charlab R; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R Clin Cancer Res; 2015 Jun; 21(12):2666-70. PubMed ID: 25802282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]